《【美国基因治疗公司】Genprex, Inc.（GNPX）美股招股说明书 S-1（2025-05-14版）（英文版）（51页）.pdf》由会员分享，可在线阅读，更多相关《【美国基因治疗公司】Genprex, Inc.（GNPX）美股招股说明书 S-1（2025-05-14版）（英文版）（51页）.pdf（51页珍藏版）》请在三个皮匠报告上搜索。

1、2025/5/15 10:35gnpx20250501_s1.htmhttps:/www.sec.gov/Archives/edgar/data/1595248/000143774925016611/gnpx20250501_s1.htm1/51S-1 1 gnpx20250501_s1.htm FORM S-1 As filed with the Securities and Exchange Commission on May 14,2025.Registration Statement No.333-UNITED STATESSECURITIES AND EXCHANGE COMMISS

2、IONWASHINGTON,D.C.20549 FORM S-1REGISTRATION STATEMENTUNDERTHE SECURITIES ACT OF 1933 GENPREX,INC.(Exact name of registrant as specified in its charter)Delaware 2834 90-0772347(State or other jurisdiction ofincorporation or organization)(Primary Standard IndustrialClassification Code Number)(I.R.S.E

3、mployerIdentification Number)3300 Bee Cave Road#650-227Austin,TX 78746(877)774-4679(Address,including zip code,and telephone number,including area code,of registrants principal executive offices)Ryan M.ConferPresident,Chief Executive Officer and Chief Financial OfficerGenprex,Inc.3300 Bee Cave Road#

4、650-227Austin,TX 78746(877)774-4679(Name,address,including zip code,and telephone number,including area code,of agent for service)Copies to:Kate Basmagian,Esq.Lowenstein Sandler LLP1251 Avenue of the AmericasNew York,New York 10020(212)262-6700Joseph M.Lucosky,Esq.Steven A.Lipstein,Esq.Lucosky Brook

5、man LLP101 Wood Avenue South,5th FloorWoodbridge,New Jersey 08830(732)395-4400 Approximate date of commencement of proposed sale to the public:As soon as practicable after the effective date of this registration statement.If any of the securities being registered on this Form are to be offered on a

6、delayed or continuous basis pursuant to Rule 415under the Securities Act of 1933 check the following box:2025/5/15 10:35gnpx20250501_s1.htmhttps:/www.sec.gov/Archives/edgar/data/1595248/000143774925016611/gnpx20250501_s1.htm2/51 If this Form is filed to register additional securities for an offering